Designer Drugs

Drugs designed and synthesized, often for illegal street use, by modification of existing drug structures (e.g., amphetamines). Of special interest are MPTP (a reverse ester of meperidine), MDA (3,4-methylenedioxyamphetamine), and MDMA (3,4-methylenedioxymethamphetamine). Many drugs act on the aminergic system, the physiologically active biogenic amines.

Also Known As:

Networked: 178 relevant articles (6 outcomes, 11 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Wada, Kiyoshi: 4 articles (05/2014 - 04/2008)
2.	Freire, Carla: 3 articles (06/2021 - 01/2018)
3.	Pho, Huy: 3 articles (06/2021 - 01/2018)
4.	Polotsky, Vsevolod Y: 3 articles (06/2021 - 01/2018)
5.	Berrocoso, Esther: 2 articles (01/2022 - 01/2022)
6.	Bravo, Lidia: 2 articles (01/2022 - 01/2022)
7.	Camarena-Delgado, Carmen: 2 articles (01/2022 - 01/2022)
8.	Llorca-Torralba, Meritxell: 2 articles (01/2022 - 01/2022)
9.	López-Martín, Carolina: 2 articles (01/2022 - 01/2022)
10.	Suárez-Pereira, Irene: 2 articles (01/2022 - 01/2022)

Related Diseases

1.	Neoplasms (Cancer) 07/01/2015 - "Considering the knowledge base of cancer signaling pathways, mechanisms of designer drug resistance should be anticipated, and early clinical trials could be designed to include arms that combine new drugs specifically with currently US Food and Drug Administration (FDA)-approved drugs expected to blunt alternative signaling pathways. " 01/01/2019 - "This minireview illustrates the growing arsenal of PPI assemblies and offers insights into how these varied PPI regulatory modalities are relevant to customized drug discovery, with a focus on cancer. " 07/01/2015 - "Successful use of anticancer designer drugs is likely to depend on simultaneous combinations of these drugs to minimize the development of resistant cancer cells. " 07/01/2015 - "Anticipating designer drug-resistant cancer cells." 10/01/2008 - "Recent advances in our understanding of the molecular abnormalities of GBM have generated new therapeutic venues of molecularly targeted agents (designer drugs) against key components of cellular pathways critical for cancer initiation and maintenance. "
2.	Seizures (Absence Seizure) 01/01/2023 - "Here we examined the efficacy of a chemogenetic tool-designer receptors exclusively activated by designer drugs (DREADDs)-for treating focal seizure in a nonhuman primate model. " 12/01/2019 - "The aim of the current study was to investigate the impact of loss of FFI within the CTC on absence seizure generation and behaviour using new Designer Receptor Exclusively Activated by Designer Drug (DREADD) technology. " 01/01/2019 - "Using a rabies virus-mediated retrograde tracing system and a designer receptors exclusively activated by designer drugs (DREADD) chemogenetic method, we demonstrated that newborn hippocampal DGCs are required for the formation of epileptic neural circuits and the induction of spontaneous recurrent seizures (SRS). " 01/01/2016 - "Here, we examined a recently developed technology, Designer Receptors Exclusively Activated by Designer Drugs (DREADDs), as a means of chemogenetic silencing to attenuate limbic seizures. " 07/01/1992 - "No seizures of designer drugs were seen. "
3.	Sleep Apnea Syndromes (Sleep Apnea) 01/01/2021 - "The main goal of our study was to determine if designer receptors exclusively activated by designer drugs (DREADD) could be used to activate the genioglossus muscle as a potential novel treatment strategy for sleep apnea. " 01/01/2021 - "Designer Receptors Exclusively Activated by Designer Drugs Approach to Treatment of Sleep-disordered Breathing." 01/01/2018 - "We applied a novel chemogenetic method to develop a mouse model of sleep disordered breathing Our goal was to reversibly silence neuromotor input to the genioglossal muscle using an adeno-associated viral vector carrying inhibitory designer receptors exclusively activated by designer drugs AAV5-hM4Di-mCherry (DREADD), which was delivered bilaterally to the hypoglossal nucleus in fifteen C57BL/6J mice. "
4.	Substance-Related Disorders (Drug Abuse) 01/01/2016 - "Designer drugs such as synthetic psychostimulants are indicative of a worldwide problem of drug abuse and addiction. " 03/25/2015 - "Clinicians should keep designer drugs in mind when evaluating substance use in young adults or in anyone presenting with acute neuropsychiatric complaints. " 08/26/2014 - "There was no relationship between bodily symmetry and smoking frequency, alcohol drinking frequency, drug or designer drug use, total substance use, age of smoking initiation, or reason of this initiation. " 08/01/2014 - "Designer drugs represent an increasingly popular form of recreational substance abuse, especially amongst young adults. " 01/01/2014 - "Designer drugs are often labeled as "not for human consumption" to circumvent drug abuse legislation. "
5.	Psychotic Disorders (Schizoaffective Disorder) 01/01/2013 - "Acutely hospitalized patients with psychosis disclosed using a new type of designer drug, previously unknown to clinicians. " 12/01/2012 - "Simultaneous detection of multiple designer drugs in serum, urine, and CSF in a patient with prolonged psychosis." 06/01/2012 - "[Designer drug induced psychosis]." 04/01/2008 - "2C-T-4 intoxication: acute psychosis caused by a designer drug." 03/25/2015 - "Acute toxicity is common and often manifests with a constellation of psychiatric and medical effects, which may be severe (e.g., anxiety, agitation, psychosis, and tachycardia), and multiple deaths have been reported with each of these types of designer drugs. "

Related Drugs and Biologics

1.	Methamphetamine (Desoxyn)
2.	Solvents
3.	Cytokine Receptors (Cytokine Receptor)
4.	Protein-Tyrosine Kinases (Tyrosine Kinase)
5.	Catecholamines
6.	Cocaine (Cocaine HCl)
7.	Cannabinoids
8.	N-Methyl-3,4-methylenedioxyamphetamine (MDMA)
9.	Illicit Drugs (Recreational Drugs)
10.	clozapine N-oxide

Related Therapies and Procedures

1.	Therapeutics
2.	Drug Therapy (Chemotherapy)
3.	Precision Medicine
4.	Secondary Prevention
5.	Chelation Therapy (Therapy, Chelation)